Biotech Values

[GrthzGd]

Another likely impetus for SNY's drop: the recent rumblings of its Board possibly to fire Mr. Viehbacher as CEO for the twin crimes of (1) moving to the Boston area, and (2) announcing a layoff of French employees due to a lack of productivity relative to those at SNY's Genzyme subsidiary in the U.S.:

www.fiercepharma.com/story/viehbachers-job-danger-some-sanofi-directors-are-agitating-change-says-les/2014-10-27?utm_medium=nl&utm_source=internal